Welcome to our dedicated page for Precigen news (Ticker: PGEN), a resource for investors and traders seeking the latest updates and insights on Precigen stock.
Overview of Precigen Inc (PGEN)
Precigen Inc is a clinical stage biopharmaceutical company that develops and refines innovative gene and cell therapies using cutting-edge synthetic biology and precision technology. With proprietary platforms such as UltraCAR-T and AdenoVerse, the company designs, builds, and regulates complex gene expression programs to address intractable diseases. Its expertise in non-viral gene transfer methods and advanced DNA construction techniques positions the company as a significant innovator across multiple therapeutic areas including immuno-oncology, autoimmune disorders, and infectious diseases.
Core Business and Technological Platforms
Precigen leverages a comprehensive suite of technologies to discover and develop next generation therapeutics. The company utilizes an advanced UltraVector platform for DNA construction, facilitating the design and assembly of gene components. Its UltraCAR-T platform, which employs a non-viral Sleeping Beauty system, enables the rapid manufacturing of personalized cell therapies with an improved safety profile and simplified logistics. Additionally, the AdenoVerse platform uses a library of engineered adenovector serotypes that efficiently deliver gene therapies aimed at modulating immune responses.
Business Model and Collaborations
The business model of Precigen is centered on leveraging its proprietary technology platforms through strategic collaborations with industry experts who bring extensive development, manufacturing, and commercial capabilities. These partnerships generate revenue primarily via technology access fees, milestone payments, royalties, and reimbursement of collaborative costs. This model provides a stable framework for continuous innovation and the effective translation of preclinical discoveries into viable clinical therapies.
Market Position and Competitive Landscape
In the competitive biotechnology arena, Precigen distinguishes itself through its robust research capabilities and a diversified portfolio of therapeutic candidates. Its unique non-viral gene transfer methods and rapid manufacturing techniques set it apart from traditional gene and cell therapy developers. By focusing resources on technologies with high clinical and commercial potential, the company addresses critical unmet needs in the therapeutic landscape, thereby reinforcing its market significance.
Operational Focus and Expertise
Precigen’s operations are built on years of scientific expertise in genetic engineering and computational model integration for therapeutic design. The company’s detailed approach to tailoring gene expression programs allows for improved functional characteristics of immune cells and precise control over therapeutic outcomes. Its methodical approach and dedication to iterative clinical development underscore its commitment to advancing medicine with precision.
Summary of Value Proposition
Precigen excels in translating complex genetic information into transformative therapies with the potential to modify the disease course in challenging therapeutic areas. By continually streamlining its research and operational models, the company ensures that its innovative techniques remain at the forefront of scientific excellence and commercial relevance. The integrated approach of technology, clinical expertise, and strategic partnerships makes Precigen a notable entity within the biopharmaceutical industry.
Precigen, Inc. (Nasdaq: PGEN) reported its second quarter and first half 2021 financial results, highlighting a total revenue increase of 10% year-over-year for Q2. However, net loss from continuing operations was $20.1 million, equivalent to $(0.10) per share. The company is advancing its clinical pipeline, with ongoing trials for PRGN-3005 and PRGN-3006 UltraCAR-T therapies and PRGN-2009 AdenoVerse immunotherapy. Precigen anticipates interim data presentations in Q4 2021, indicating a pivotal year for its innovative therapies.
Precigen, a biopharmaceutical company focused on gene and cell therapies, will release its second quarter and first half 2021 financial results after market close on August 9, 2021. A conference call will be held at 4:05 PM ET on the same day to discuss the results and provide a business update. Investors can access the call by dialing specific numbers or register through the company's website. Precigen emphasizes its commitment to innovative therapies targeting critical diseases, enhancing its pipeline direction toward clinical proof-of-concept.
Precigen ActoBio announced positive topline results from its ongoing Phase 1b/2a clinical study of AG019 ActoBiotics for treating recent-onset type 1 diabetes (T1D). The treatment targets autoimmune responses by delivering human proinsulin and interleukin-10 to induce regulatory T cells. Results show that 56% of adult patients receiving AG019 monotherapy stabilized or increased C-peptide levels. In combination therapy with teplizumab, 70% of adults and 100% of adolescents had similar results. The therapy appears safe, with no serious adverse events reported, paving the way for future studies.
Precigen, Inc. (Nasdaq: PGEN) announced that Dr. Helen Sabzevari, President and CEO, will participate in a fireside chat at the JMP Securities Life Sciences Conference on June 17, 2021, at 11:00 AM ET. The event will be accessible through Precigen's website in the Events & Presentations section. The company focuses on innovative gene and cell therapies targeting urgent diseases in immuno-oncology, autoimmune disorders, and infectious diseases. Precigen aims to advance affordable biotherapeutics and has a robust pipeline moving toward clinical proof-of-concept.
Precigen, Inc. (Nasdaq: PGEN) reported its Q1 2021 financial results, highlighting significant advancements in its clinical trials. The UltraCAR-T therapies, PRGN-3005 and PRGN-3006, showcased promising safety profiles and clinical activities, with ongoing dose escalation phases. The company initiated the PRGN-2012 study, received orphan drug designations for multiple therapies, and anticipates upcoming data presentations. Financially, total revenues fell by 18% to $24.5 million, attributed mainly to decreased collaboration revenues. However, total cash on hand stands at $209.3 million.
Precigen, a biopharmaceutical company, announced that Chief Financial Officer Rick Sterling will step down effective April 2, 2021, by mutual agreement. The company is actively seeking a qualified successor to support its transition from a clinical-stage to a commercial organization. CEO Helen Sabzevari highlighted the importance of this role in maintaining growth momentum and preparing for commercial readiness of their lead products. Precigen specializes in gene and cell therapies aimed at addressing urgent diseases, particularly in immuno-oncology and autoimmune disorders.
On March 23, 2021, Precigen announced that the first patient has been dosed in a Phase I study of PRGN-2012, an off-the-shelf immunotherapy targeting recurrent respiratory papillomatosis (RRP). Recently granted Orphan Drug Designation by the FDA, PRGN-2012 utilizes gorilla adenovector technology to generate immune responses against HPV 6 and HPV 11. The trial aims to assess the safety and tolerability of PRGN-2012, involving up to 12 patients at maximum tolerated doses. This milestone could provide RRP patients with new therapeutic options, reducing the need for repeat surgeries.
Precigen, a biopharmaceutical company, announced that the FDA granted orphan drug designation for its investigational immunotherapy PRGN-2012, aimed at treating recurrent respiratory papillomatosis (RRP). This designation provides access to various incentives that may expedite development and commercialization. PRGN-2012, developed in collaboration with the National Cancer Institute, utilizes gorilla adenovector technology to prompt immune responses against HPV 6 and 11. The condition affects a small population, making novel treatments critically needed. CEO Helen Sabzevari emphasized the urgency for new therapies.
Precigen, Inc. (Nasdaq: PGEN) announced its financial results for Q4 and the full year 2020, reporting total revenues of $103.2 million, up from $90.7 million in 2019. The company experienced a net loss of $103.8 million or $(0.62) per share. Despite challenges, Precigen raised $129.4 million from a public offering in January 2021, ensuring cash support through 2023. Key developments include promising preliminary clinical data for PRGN-3005 and PRGN-3006 UltraCAR-T therapies, paving the way for future trials.
Precigen, Inc. (Nasdaq: PGEN) will release its fourth quarter and full year 2020 financial results after market close on March 1, 2021. A conference call is scheduled for 4:30 PM ET that day to discuss the results and provide a business update. Helen Sabzevari, PhD, President and CEO, will also present at the H.C. Wainwright Virtual Global Life Sciences Conference starting March 9, 2021. The company is focused on advancing gene and cell therapies targeting serious diseases, with ongoing clinical trials and a commitment to innovation in therapeutics.
FAQ
What is the current stock price of Precigen (PGEN)?
What is the market cap of Precigen (PGEN)?
What is the primary focus of Precigen Inc?
How does Precigen generate revenue?
What distinguishes Precigen's technological platforms?
Which therapeutic areas does Precigen target?
How is Precigen positioned in the competitive biotechnology landscape?
What role do partnerships play in Precigen's business model?
